Chimerix turns $39m into $935m
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
A pivotal push from BeiGene
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Will Roche's Perseverance pay off?
Giredestrant will soon become the first oral SERD to yield first-line data.
Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
